Inflammatory Diseases

Prevalence

50.7 / 100K

Incidence

5.0 / 100K/yr

19 drugs in development·15 companies·0 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
bexobrutideg	Nurix Therapeutics, Inc. (NRIX)

Phase 2(2)

Drug	Company
etokimab	ANAPTYSBIO, INC (ANAB)
prt2761	PORTOLA PHARMACEUTICALS INC (PTLA)

Phase 1(3)

Drug	Company
ANB101	ANAPTYSBIO, INC (ANAB)
frtx-02	Fresh Tracks Therapeutics, Inc. (FRTX)
wtx-921	Werewolf Therapeutics, Inc. (HOWL)

Preclinical(10)

Drug	Company
CPI-182	Corvus Pharmaceuticals, Inc. (CRVS)
cts-2090	Histogen Inc. (HSTO)
cts-2096	Histogen Inc. (HSTO)
CUE-401	Cue Biopharma, Inc. (CUE)
EPS-3903	ENANTA PHARMACEUTICALS INC (ENTA)
ht-alz	Hoth Therapeutics, Inc. (HOTH)
KT-295	Kymera Therapeutics, Inc. (KYMR)
lb-1	ProPhase Labs, Inc. (PRPH)
lb-2	ProPhase Labs, Inc. (PRPH)
man-dex	NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB)

Unknown(3)

Drug	Company
Next generation bispecific antibody platform	Celldex Therapeutics, Inc. (CLDX)
Remicade	Merck & Co., Inc. (MRK)
Simponi	Merck & Co., Inc. (MRK)

BioSniper tracks 19 drugs in development for Inflammatory Diseases across 15 companies.

The estimated prevalence of Inflammatory Diseases is approximately 50.7 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.